Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials

Published:2016-11-23 Issue:12 Volume:5 Page:3454-3463
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Xin Yong¹²,Guo Wen Wen²,Huang Qian²,Zhang Pei²,Zhang Long-Zhen²,Jiang Guan³,Tian Ye¹

Affiliation:

1. Department of Radiotherapy and Oncology; The Second Affiliated Hospital of Soochow University; Suzhou China

2. Department of Radiation Oncology; Affiliated Hospital of Xuzhou Medical College; Xuzhou 221002 China

3. Department of Dermatology; Affiliated Hospital of Xuzhou Medical College; Xuzhou 221002 China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference20 articles.

1. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence;Valachis;Breast Cancer Res. Treat.,2012

2. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

3. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study;Guarneri;J. Clin. Oncol.,2012

4. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study;Blackwell;J. Clin. Oncol.,2012

5. Lapatinib combined with neoadjuvant paclitaxel trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials;Sun;Oncol. Lett.,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

2. Can We Find A Noninvasive Tool of Precision Medicine That Can Always Be Used For the Individualized Treatment of Women With Breast Cancer?;The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach;2023-12-18

3. Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer;Pharmaceuticals;2023-05-26

4. Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review;Indian Journal of Physiology and Pharmacology;2022-05-31

5. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations;International Journal of Radiation Oncology*Biology*Physics;2021-12